Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

Europa Stream

 

Alcon to acquire STAAR Surgical for US $1.5bn

Alcon’s planned purchase of STAAR Surgical adds the latter’s EVO ICL lens technology to its refractive surgery portfolio, aiming to broaden treatment options for myopia and strengthen its position in a market seeing significant deal activity.

France targets PE-owned medical labs with profit caps

Despite upcoming profit caps and tighter regulations, France’s medical laboratory sector remains large and resilient. It still offers opportunities for investors in regional and tech-driven labs able to navigate tighter margins.

Bupa’s elderly care revenues surge

British multinational health insurer Bupa published their half year financial report last week, showing strong profits from elderly care performance. 

Assura shareholders give final approval to PHP takeover

UK healthcare real estate investor Assura has voted to accept a bid from Primary Health Properties (PHP), the only other UK REIT with a significant primary care portfolio. The decision brings an end to a takeover contest with US private equity firm KKR.

French pharmaceutical company Servier in “exclusive negotiations” to sell Biogaran to UK’s BC Partners

With France facing persistent medicine shortages and heightened political focus on healthcare sovereignty, the generic pharmaceuticals sector is drawing increased attention from private investors and policymakers alike. Growing interest in maintaining domestic production and securing supply chains has positioned French generics as both a strategic asset and a market opportunity.

From 0 to 250%: EU pharma and Trump’s tariffs

Last month, HBI covered how EU tariff negotiations would affect pharma prices. At that time, Donald Trump had been threatening a 50% tariff on all EU imports and a 200% tariff on pharmaceutical imports, creating much uncertainty around the final state of the trade deal. On Tuesday, however, Trump told CNBC that while the tariffs on pharmaceuticals may be “small” initially, in a year's time they will be increased to 150% and then 250%.

Germany’s 1Q Health Group acquires Beauty Production, expanding European CDMO platform

Germany-based Contract Development and Manufacturing Organisation (CDMO) 1Q Health Group, backed by European private equity firm Nord Holding, has acquired Beauty Production GmbH, a contract manufacturer specialising in liquid dietary supplements and cosmetics. HBI spoke with Holger Ebersberger, who is a private equity partner at McDermott Will & Schulte in Munich, to discuss his views on the acquisition, current deal activity in the CDMO and health manufacturing sectors across Germany and Europe, and the key factors driving investment in these areas.

Find Us